Prognostic value of serum IL-2，IL-6，IL-8 and IL-10 in patients with irritable bowel syndrome

doi:10.3969/j.issn.1673-8640.2024.09.010

Abstract

Abstract:

Objective To investigate the roles of serum interleukin（IL）-2，IL-6，IL-8 and IL-10 in the evaluation of poor prognosis in patients with irritable bowel syndrome （IBS）. Methods A total of 102 patients with IBS were enrolled from Qinghai Provincial Hospital of Traditional Chinese Medicine from February 2020 to December 2022. All the patients were followed up for 3 months and classified into poor prognosis group and good prognosis group. The general data of all the patients were collected，and blood routine test items [white blood cell（WBC） count，the absolute value of lymphocytes （LYMPH#） and the absolute value of neutrophils （NEUT#） ] and serum C-reactive protein （CRP），procalcitonin （PCT），IL-2，IL-6，IL-8 and IL-10 were determined before treatment. Spearman correlation analysis was used to evaluate the correlation between various indicators and poor prognosis in patients with IBS. Logistic regression analysis was used to evaluate the risk factors for poor prognosis in patients with IBS. The efficacy of serum IL-2，IL-6，IL-8 and IL-10 in determining poor prognosis in patients with IBS was evaluated by receiver operating characteristic （ROC） curve. Results Among the 102 patients with IBS，28 cases had poor prognosis，and 74 cases had good prognosis. Before treatment，serum IL-2，IL-6 and IL-8 levels in poor prognosis group were higher than those in good prognosis group （P<0.01），and serum IL-10 levels were lower than those in good prognosis group （P<0.001）. There was no statistical significance among WBC count，LYMPH#，NEUT#，CRP and PCT levels between the 2 groups （P>0.05）. IL-2，IL-6 and IL-8 were positively correlated with poor prognosis in IBS patients （r=0.445，0.445 and 0.343，P<0.01），and they were negatively correlated with IL-10 （r=-0.402，P<0.01）. The increase of IL-2，IL-6 and IL-8 and the decrease of IL-10 were all independent risk factors for poor prognosis in IBS patients [odds ratios （OR） were 1.803，1.379，1.133 and 0.769，95% confidence intervals （CI） were 1.307-2.488，1.152-1.651，1.001-1.282 and 0.651-0.908，respectively，P<0.05]. The areas under curves （AUC） of serum IL-2，IL-6，IL-8 and IL-10 were 0.788，0.788，0.722，0.760 and 0.945 for the poor prognosis of patients with IBS. Conclusions he combined determination of serum IL-2，IL-6，IL-8 and IL-10 is helpful to evaluate the poor prognosis of patients with IBS.

Key words: Interleukin-2, Interleukin-6, Interleukin-8, Interleukin-10, Irritable bowel syndrome

CLC Number:

R446.1

QUAN Rongrong, WANG Min. Prognostic value of serum IL-2，IL-6，IL-8 and IL-10 in patients with irritable bowel syndrome[J]. Laboratory Medicine, 2024, 39(9): 875-879.

Figures/Tables 5

References 24

[1]	王雪娇, 孙章胤, 纪昌春. 腹泻型肠易激综合征与免疫功能相关性研究进展[J]. 中国医药导报, 2023, 20(20):39-42.
[2]	罗梅, 熊理守. 肠易激综合征诊断的研究进展[J]. 国际消化病杂志, 2023, 43(2):77-80.
[3]	赵尔樱, 周佳玮, 褚海云, 等. 肠易激综合征流行病学与致病因素研究进展[J]. 中国公共卫生, 2021, 37(4):764-768.
[4]	孟煜凡. 肠易激综合综合征发病机制的最新研究进展[J]. 临床医药文献电子杂志, 2020, 7(52):197-198.
[5]	宋军, 侯晓华. 胃肠道感染与功能性胃肠病研究现状[J]. 胃肠病学和肝病学杂志, 2019, 28(4):365-367.
[6]	CAI L L, LI X, CAI Q H, et al. Irritable bowel syndrome in children:the placebo response rate and influencing factors a meta-analysis[J]. Pediatr Res, 2024, 95(6):1432-1440.
[7]	VARA E J, BROKSTAD K A, HAUSKEN T, et al. Altered levels of cytokines in patients with irritable bowel syndrome are not correlated with fatigue[J]. Int J Gen Med, 2018,11:285-291.
[8]	IVASHKIN V, POLUEKTOV Y, KOGAN E, et al. Disruption of the pro-inflammatory,anti-inflammatory cytokines and tight junction proteins expression,associated with changes of the composition of the gut microbiota in patients with irritable bowel syndrome[J]. PLoS One, 2021, 16(6):e0252930.
[9]	BASHASHATI M, MORADI M, SAROSIEK I. Interleukin-6 in irritable bowel syndrome:a systematic review and meta-analysis of IL-6(-G174C)and circulating IL-6 levels[J]. Cytokine, 2017,99:132-138.
[10]	中华医学会消化病学分会胃肠功能性疾病协作组, 中华医学会消化病学分会胃肠动力学组. 2020年中国肠易激综合征专家共识意见[J]. 中华消化杂志, 2020, 40(12):803-818.
[11]	中华中医药学会脾胃病分会, 温艳东, 李保双, 等. 消化系统常见病肠易激综合征中医诊疗指南(基层医生版)[J]. 中华中医药杂志, 2020, 35(7):3518-3523.
[12]	SEBASTIÁN DOMINGO J J. Irritable bowel syndrome[J]. Med Clin(Barc), 2022, 158(2):76-81.
[13]	GRAYSON M. Irritable bowel syndrome:4 big questions[J]. Nature, 2016, 533(7603):S118.
[14]	MUSCATELLO M R, BRUNO A, MENTO C, et al. Personality traits and emotional patterns in irritable bowel syndrome[J]. World J Gastroenterol, 2016, 22(28):6402-6415.
[15]	LUPU V V, GHICIUC C M, STEFANESCU G, et al. Emerging role of the gut microbiome in post-infectious irritable bowel syndrome:a literature review[J]. World J Gastroenterol, 2023, 29(21):3241-3256.
[16]	ISMAIL M H, MOLAN A L, ABBAS S K. Serological levels of cytokines in irritable bowel syndrome(IBS)patients and non-IBS subjects with and without Blastocystis spp. infection[J]. Ann Parasitol, 2022, 68(1):77-85.
[17]	NG Q X, SOH A Y S, LOKE W, et al. The role of inflammation in irritable bowel syndrome(IBS)[J]. J Inflamm Res, 2018,11:345-349.
[18]	CHEN J, ZHANG Y, DENG Z. Imbalanced shift of cytokine expression between T helper 1 and T helper 2(Th1/Th2)in intestinal mucosa of patients with post-infectious irritable bowel syndrome[J]. BMC Gastroenterol, 2012,12:91.
[19]	KYRIAN O, DOROFEYEV A, DERKACH I, et al. Evaluation of the impact of some single-nucleotide gene polymorphisms on the development of adenomatous polyps of the colon in patients with irritable bowel syndrome[J]. Turk J Gastroenterol, 2023, 34(8):822-830. DOI PMID
[20]	肖樱艳, 崔艳, 李艳. 肠道菌群与IL-6/gp130信号通路在急性胰腺炎发病机制中的研究进展[J]. 检验医学, 2021, 36(5):565-568. DOI
[21]	BASHASHATI M, REZAEI N, SHAFIEYOUN A, et al. Cytokine imbalance in irritable bowel syndrome:a systematic review and meta-analysis[J]. Neurogastroenterol Motil, 2014, 26(7):1036-1048.
[22]	CHOGHAKHORI R, ABBASNEZHAD A, HASANVAND A, et al. Inflammatory cytokines and oxidative stress biomarkers in irritable bowel syndrome:association with digestive symptoms and quality of life[J]. Cytokine, 2017,93:34-43.
[23]	OGŁODEK E. Changes in the serum levels of cytokines:IL-1β,IL-4,IL-8 and IL-10 in depression with and without posttraumatic stress disorder[J]. Brain Sci, 2022, 12(3):387.
[24]	QIN S Y, JIANG H X, LU D H, et al. Association of interleukin-10 polymorphisms with risk of irritable bowel syndrome:a meta-analysis[J]. World J Gastroenterol, 2013, 19(48):9472-9480.

组别	例数	性别		年龄/岁	IBS病程/年	BMI/ （kg·m-2）	基础疾病			吸烟史/例	饮酒史/例
组别	例数	男/例	女/例	年龄/岁	IBS病程/年	BMI/ （kg·m-2）	高血压/例	2型糖尿病/例	冠心病/例	吸烟史/例	饮酒史/例
预后不良组	28	16	12	39.39±7.39	4.07±1.59	23.07±1.95	6	7	4	19	14
预后良好组	74	43	31	37.82±6.49	4.41±1.59	23.15±2.41	15	14	11	46	33
统计值		0.008		1.049	0.949	0.158	0.017	0.459	0.005	0.285	0.239
P值		0.930		0.297	0.345	0.875	0.897	0.498	0.941	0.593	0.625

组别	例数	性别		年龄/岁	IBS病程/年	BMI/ （kg·m-2）	基础疾病			吸烟史/例	饮酒史/例
组别	例数	男/例	女/例	年龄/岁	IBS病程/年	BMI/ （kg·m-2）	高血压/例	2型糖尿病/例	冠心病/例	吸烟史/例	饮酒史/例
预后不良组	28	16	12	39.39±7.39	4.07±1.59	23.07±1.95	6	7	4	19	14
预后良好组	74	43	31	37.82±6.49	4.41±1.59	23.15±2.41	15	14	11	46	33
统计值		0.008		1.049	0.949	0.158	0.017	0.459	0.005	0.285	0.239
P值		0.930		0.297	0.345	0.875	0.897	0.498	0.941	0.593	0.625

组别	例数	WBC计数/（×109·L-1）	LYMPH#/（×109·L-1）	NEUT#/（×109·L-1）	CRP/（mg·L-1）
预后不良组	28	6.41±1.87	1.86±0.52	2.28±0.89	9.72±3.05
预后良好组	74	6.18±2.16	1.91±0.55	2.35±0.88	9.95±2.65
t值		0.490	0.427	0.344	0.378
P值		0.625	0.670	0.732	0.707
组别	PCT/（ng·L-1）	IL-2/（pg·mL-1）	IL-6/（pg·mL-1）	IL-8/（pg·mL-1）	IL-10/（pg·mL-1）
预后不良组	0.38±0.14	10.56±3.08	18.23±5.08	24.89±5.70	8.58±3.65
预后良好组	0.37±0.11	7.12±2.77	13.35±3.67	20.12±6.66	12.68±4.62
t值	0.247	5.422	5.363	3.348	4.224
P值	0.805	<0.001	<0.001	0.001	<0.001

组别	例数	WBC计数/（×109·L-1）	LYMPH#/（×109·L-1）	NEUT#/（×109·L-1）	CRP/（mg·L-1）
预后不良组	28	6.41±1.87	1.86±0.52	2.28±0.89	9.72±3.05
预后良好组	74	6.18±2.16	1.91±0.55	2.35±0.88	9.95±2.65
t值		0.490	0.427	0.344	0.378
P值		0.625	0.670	0.732	0.707
组别	PCT/（ng·L-1）	IL-2/（pg·mL-1）	IL-6/（pg·mL-1）	IL-8/（pg·mL-1）	IL-10/（pg·mL-1）
预后不良组	0.38±0.14	10.56±3.08	18.23±5.08	24.89±5.70	8.58±3.65
预后良好组	0.37±0.11	7.12±2.77	13.35±3.67	20.12±6.66	12.68±4.62
t值	0.247	5.422	5.363	3.348	4.224
P值	0.805	<0.001	<0.001	0.001	<0.001

项目	β值	标准误	Wald值	P值	OR值（95%CI）
IL-2	0.590	0.164	12.888	<0.001	1.803（1.307~2.488）
IL-6	0.321	0.092	12.223	<0.001	1.379（1.152~1.651）
IL-8	0.125	0.063	3.890	0.049	1.133（1.001~1.282）
IL-10	-0.263	0.085	9.604	0.002	0.769（0.651~0.908）